Delcath Systems (NASDAQ:DCTH) Posts Earnings Results, Beats Expectations By $0.07 EPS

Delcath Systems (NASDAQ:DCTH) issued its quarterly earnings data on Thursday. The company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.07, FiscalAI reports. The business had revenue of $24.99 million for the quarter, compared to analysts’ expectations of $23.51 million. Delcath Systems had a net margin of 0.62% and a return on equity of 0.51%.

Here are the key takeaways from Delcath Systems’ conference call:

• Q1 operational momentum: the company activated 4 centers, reported record new patient starts, has 29 REMS?certified sites and is modifying its activation goal to 37 centers by year?end (40 by Q1 2027), reflecting broad commercial interest.
• Strong topline and guidance: Q1 revenue rose to $25.0M (vs $19.8M LY), ending cash of $89.3M, and management reiterated at least $100M revenue for 2026 with expected positive adjusted EBITDA for the remainder of the year.
• Clinical programs progressing but paced slowly: the metastatic CRC trial has 13 active screening sites with 7 patients enrolled (target 26 sites by year?end; interim readout late 2027) and the metastatic breast program has 4 sites active with a target of 15 by late 2026, so readouts remain long?dated and enrollment is ramping.
• CHOPIN data driving adoption: publication of the CHOPIN results in The Lancet Oncology (combination HEPZATO + immunotherapy showing ~76% response and survival separation) is cited as a key factor changing prescribing patterns and motivating many new sites to adopt a CHOPIN?like protocol.

Delcath Systems Trading Up 2.1%

DCTH stock traded up $0.24 during trading on Friday, reaching $11.48. 569,665 shares of the stock were exchanged, compared to its average volume of 339,366. The business has a 50 day moving average price of $9.86 and a 200-day moving average price of $9.82. Delcath Systems has a 1 year low of $8.12 and a 1 year high of $18.23. The firm has a market capitalization of $395.60 million, a price-to-earnings ratio of 1,148.00 and a beta of 0.54.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on DCTH. Evercore set a $27.00 price target on shares of Delcath Systems in a research note on Thursday, February 26th. BTIG Research dropped their price target on shares of Delcath Systems from $23.00 to $19.00 and set a “buy” rating on the stock in a research note on Thursday, February 26th. Wall Street Zen cut shares of Delcath Systems from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. Finally, HC Wainwright restated a “buy” rating and issued a $30.00 price objective on shares of Delcath Systems in a report on Friday, January 9th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $22.50.

Hedge Funds Weigh In On Delcath Systems

A number of institutional investors have recently bought and sold shares of DCTH. Nantahala Capital Management LLC purchased a new position in Delcath Systems during the third quarter worth about $7,164,000. Marshall Wace LLP purchased a new stake in Delcath Systems in the 2nd quarter valued at about $6,572,000. Rosalind Advisors Inc. raised its holdings in Delcath Systems by 13.8% in the 2nd quarter. Rosalind Advisors Inc. now owns 3,300,389 shares of the company’s stock valued at $44,885,000 after buying an additional 400,000 shares during the period. Goldman Sachs Group Inc. raised its holdings in Delcath Systems by 116.0% in the 4th quarter. Goldman Sachs Group Inc. now owns 587,678 shares of the company’s stock valued at $5,936,000 after buying an additional 315,583 shares during the period. Finally, Lane Generational LLC purchased a new stake in Delcath Systems in the 4th quarter valued at about $1,997,000. 61.12% of the stock is owned by hedge funds and other institutional investors.

About Delcath Systems

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.